This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
This is a web analytics service.
Processing company
  • Zoom Analytics Ltd.
  • Petah Tikva, Israel
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
Hemofarm Marks 59 Years of Successful Operation
31. May 2019.

RECORD-BREAKING PRODUCTION ACCOMPANIED BY RECORD-BREAKING SALES

The leader in the pharmaceutical market of Serbia and the region and one of the largest exporters in Serbia, Hemofarm marked 59 years of successful operations. Hemofarm finished the previous year with a record-breaking output of 5.6 billion tablets when it also achieved record-breaking sales, it was pointed out at the traditional reception for employees, jubilarians, and pensioners in Vršac-based factory.

Hemofarm's success in Serbia is accompanied by results of factories in Bosnia and Herzegovina and Montenegro: Banja Luka-based Hemofarm is still a leader in B&H with a sales growth of 18%, while Podgorica-based Hemofarm achieved record-breaking production output in the past year. There were 318 people employed with Hemofarm Group in the last 12 months, i.e. between the two Company anniversaries.

State-of-the-art Hemofarm plants are in compliance with the highest international pharmaceutical standards and, with the high professionalism of staff, this company has become a guarantor of medicinal product quality for numerous European countries. As a result, over the past 10 years, production of more than 230 medicinal products has been transferred from European Union factories to Hemofarm production plants. According to the CEO of Hemofarm, Dr. Ronald Seeliger, it is precisely such company's willingness to adapt to the global market requirements, which is one of the main reasons for its success.

’Hemofarm, for example, has been prepared to implement the EU Falsified Medicines Directive (FMD) even before the deadline, which has been mandatory for all entities in the pharmaceutical supply chain as of February 9th this year. Without full implementation of this directive, we would not be able to export medicinal products to the European Union market, and Hemofarm has been delivering medicines in accordance with the new EU regulations, prior to the set deadline, i.e. since the beginning of the year’, - Dr. Seeliger pointed out on the occasion of Company Day.

According to him, every result is important for Hemofarm. ’Production and sales volume is the main indicator of success of each company, and we are proud of each individual result: the success that our medicinal product or preparation achieves in the market, the digitization process in our laboratories, the fact that many students have been employed in Hemofarm upon completion of studies. Each of these factors participates in the construction of company’s overall success’.

A great jubilee ahead of us

’We've gone a long way since the first product came out of our production lines 59 years ago. Now we are entering the great jubilee - the 60th year of operations. We have prepared many novelties for the upcoming period, with a clear intention to celebrate the past, and to look forward to the future’, Dr. Ronald Seeliger, Hemofarm’s CEO, said.